Stockscreener 앱 받기
12.17
0.00%
0.00
Oculis Holding Ag 주식(OCS)의 최신 뉴스
Enterprise value to revenue forward of Oculis Holding AG – FWB:CR5 - TradingView
Oculis (OCS) Daily Review: Rises 0.38% to $13.19 at the Close; Chart Reference: $12.53 and $13.85 Define the Nearby Reference Levels for the Current SessionAnchored VWAP - vinanet.vn
Oculis (OCSAW) Session-Level Review: Ends Up by 6.00% at $5.04 in the Latest Session; Current Setup: the Near-Term Reference Band Stretches From $4.79 to $5.29 in the Current UpdateAggressive Growth Picks - vinanet.vn
Oculis Holding (OCS) Advances 0.94% as Shares Hold Above Key SupportDouble Top - vinanet.vn
Stifel reiterates Buy rating on Oculis stock, $40 target By Investing.com - Investing.com Nigeria
The Technical Signals Behind (OCS) That Institutions Follow - Stock Traders Daily
Four Oculis directors' restricted stock units vest in Aug. 13 notifications - Stock Titan
Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - Zacks Investment Research
Stifel reiterates Buy rating on Oculis stock, $40 target - Investing.com
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.50 as Consolidation Range NarrowsVolatility Breakout Picks - Vinanet
Oculis buys out privosegtor’s global rights from Accure - Glance by Eyes On Eyecare
HC Wainwright Has Negative Estimate for Oculis Q3 Earnings - MarketBeat
Oculis rebuilds pipeline with Privosegtor buy from Accure - AllSci
Oculis Holding AG (OCS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oculis Announces Asset Purchase Agreement With Accure Therapeutics, Posts Q2 2026 Financial Results - VisionMonday.com
Oculis Holding (OCS) inks $3.8M cash-plus-shares deal for Privosegtor rights - Stock Titan
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company - The Manila Times
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, ... - pmg-ky3.com
Oculis to buy Accure rights to Privosegtor for $3.8 million plus up to 2,050,000 shares - Bitget
Oculis acquires full rights to Privosegtor, boo... - Pluang
Oculis to Acquire Full Global Rights to Privosegtor from Accure Therapeutics in Strategic Asset Purchase - Quiver Quantitative
Oculis Signs Asset Purchase Agreement with Accure - GlobeNewswire
Oculis Holding AG (OCS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results - MarketBeat
Oculis Holding AG (OCS) stock price, news, quote and history - Yahoo Finance UK
Oculis Holding earnings beat by CHF0.23, revenue topped estimates - Investing.com Nigeria
Wall Street Zen Upgrades Oculis (NASDAQ:OCS) to Sell - MarketBeat
Oculis Holding AG (OCS) Stock News Today - TradingKey
Oculis Holding AG (OCS) Stock Analysis: Navigating a 190.92% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Oculis Holding AG Stock 12‑Month Price Target Cut to $36.26, Implies 193% Upside - TradingView
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Oculis Holding AG reports results for the quarter ended June 30Earnings Summary - TradingView
Oculis Q2 2026 Results: Finance Gains Narrow the Net Loss Despite Higher Costs - TradingKey
OCS: Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth - TradingView
Oculis (NASDAQ: OCS) pivots to neuro-ophthalmology as H1 loss falls - stocktitan.net
Oculis Reports Q2 2026 Financial Results and Provides Company Update - The Manila Times
Earnings To Watch: Oculis Holding AG (OCS) Reports Q2 2026 Result - Yahoo Finance
Precision Trading with Oculis Holding Ag (OCS) Risk Zones - Stock Traders Daily
Oculis Receives Positive FDA Feedback for Privosegtor Development in Acute Multiple Sclerosis Relapses - Quiver Quantitative
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses - Yahoo Finance Singapore
FDA Says Oculis Can Cross-Reference Data for Planned MS Relapse Trial - Stock Titan
Oculis Holding (OCS) Holds Near $11.31 as Buyers Defend Key Support ZoneStock Picks - vinanet.vn
Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Oculis Holding AG Revenue Breakdown – NASDAQ:OCSAW - TradingView
Insiders At Oculis Holding Sold CHF1.0m In Stock, Alluding To Potential Weakness - simplywall.st
OCS|Oculis Holding AG|Price:10.952|Chg%:-0.068 - TradingKey
Oculis Holding AG (OCS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OCS|Oculis Holding AG|Price:11.010|Chg%:-0.120 - TradingKey
Oculis Holding AG (OCS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oculis Holding AG (OCS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oculis Holding AG (OCS) Institutional Confidence - TradingKey
Oculis Holding AG (OCS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oculis Holding AG (OCS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oculis Holding AG (OCS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oculis Holding AG (OCS) Balance Sheet - TradingKey
Oculis Holding AG (OCS) Cash Flow - TradingKey
0.86%
0.31%
자본화:
|
볼륨(24시간):